Oxford Immunotec Announces Data Presentations for T-SPOT®.CMV Test at the 2018 American Transplant Congress
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that data from studies utilizing the T-SPOT.CMV test will be presented at the American Transplant Congress (ATC) taking place June 2 – 6, 2018 in Seattle, Washington.
The following abstracts will be presented during the Cytomegalovirus (CMV): Bench to Bedside Session being held today, Monday, June 4 from 2:30 PM – 4:00 PM PT.
- CMV-Specific Cell-Mediated Immunity after Valgancyclovir Prophylaxis Predicts Late Onset CMV Infection in Kidney Transplant Patients -- Abstract #184
- Prospective, Multi-Center Observational Study of Cell-Mediated Immunity for Cytomegalovirus Infection in Kidney Transplant Recipients (Data from the PROTECT Study1) -- Abstract #187
- T-Cell Depletion Does Not Increase the Risk of CMV Infection in Donor-Positive, Recipient-Negative Kidney Transplants Due to the Absence of Preformed CMV-Specific Cell-Mediated Immunity -- Abstract #188
“We are pleased that the results of the now-completed PROTECT study show that our T-SPOT.CMV test accurately predicts post-kidney transplant CMV infection,” said Dr. Richard Wenstrup, Chief Medical Officer of Oxford Immunotec. “This data, as well as the data generated from the two European studies, indicate that measurement of CMV-specific cell-mediated immunity by T-SPOT.CMV will allow improved, individualized management of CMV infection risk both prior to and post transplant. We are excited about the potential application of T-SPOT.CMV in transplant medicine and the clinical and economic value the assay could bring to this setting.”
1 The PROTECT Study: A Prospective Observational Trial to Evaluate the Correlation of T-SPOT Response to CMV Infection and T Cell-Mediated Acute Graft Rejection
About the T-SPOT.CMV test
The T-SPOT.CMV test leverages Oxford Immunotec's proprietary T-SPOT technology platform to measure the strength of a patient’s cellular immune response to antigens specific to cytomegalovirus, or CMV. The T-SPOT.CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV infection. T cell immunity against CMV is a factor in controlling viral latency and susceptibility to CMV infection, a common and serious complication in both solid organ and stem cell transplantation. CMV can affect individuals with weaknesses in their T cell response and it is therefore an important and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media and Investor Inquiries:
Head of Strategy and Investor Relations
Tel: +1 (508) 556-1377